The Efficacy and Safety of Local 5-aminolevulinic Acid-based Photodynamic Therapy in the Treatment of Cervical High-grade Squamous Intraepithelial Lesion: a Single Center Retrospective Observational Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 May 2

PMID 38694787

Authors

Jing Qian

Yahui Wang

Guihong Wu

Junlei Lu

Liping Sun

Song Xu

Affiliations

Soon will be listed here.

Abstract

Background: Typical treatments for cervical high-grade squamous intraepithelial lesion (HSIL) are invasive procedures. However, these procedures often come with several severe side effects, despite their positive effects on cervical HSIL. 5-aminolevulinic acid photodynamic therapy (ALA-PDT) is a non-invasive treatment that has been successfully used to treat cervical low-grade squamous intraepithelial lesion (LSIL). In this study, we aimed to further investigate the clinical efficacy and safety of ALA-PDT in the treatment of patients with cervical HSIL.

Methods: A total of 40 patients aged 20 - 41 years with cervical HSIL and high-risk Human Papilloma Virus (HR-HPV) infections were enrolled in this retrospective study from January 2019 to December 2022. Patients were treated with six times of ALA-PDT at intervals of 7-14 days. Three months after the treatment, the efficacy was evaluated through HPV genotyping and cervical cytology examination. If the cytological result was worse than ASC -US, the patient underwent colposcopy-directed biopsy immediately. Otherwise, patients would receive rigorous follow-up observation.

Results: Three months after receiving ALA-PDT treatment, 65% (26/40) of cervical HSIL patients at our center showed complete regression (cytological result: normal; HR-HPV: negative). This rate increased to 82.5% (33/40) at the 12-month follow-up. None of the patients experienced disease progression after ALA-PDT therapy. The risk of persistent HR-HPV infection was 32.5% (13/40) at the 3-month follow-up after ALA-PDT. Multivariate analyses identified cervical canal involvement as an independent risk factor for persistent HR-HPV infection at the 3-month follow-up after ALA-PDT treatment. During the treatment of the 40 patients with ALA-PDT, there were no reports of severe adverse reactions. Only a limited number of patients experienced slight discomfort symptoms.

Conclusion: ALA-PDT is safe and effective noninvasive therapy for patients with cervical HSIL and HR-HPV infections. It is particularly suitable for young women, who have been confirmed with cervical HSIL and have demand for fertility protection. Three months after ALA-PDT treatment, if a patient still has either ASC-US cervical cytological result and/or HR-HPV infection, rigorous observation is considered safe for her. Cervical canal involvement is an independent risk factor for persistent HR-HPV infection at the 3-month follow-up after ALA-PDT treatment.

References

McCredie M, Sharples K, Paul C, Baranyai J, Medley G, Jones R . Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008; 9(5):425-34. DOI: 10.1016/S1470-2045(08)70103-7. View

Jin G, Lanlan Z, Li C, Dan Z . Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis. Arch Gynecol Obstet. 2013; 289(1):85-99. DOI: 10.1007/s00404-013-2955-0. View

Qiu L, Li J, Chen F, Wang Y, Wang Y, Wang X . Chinese expert consensus on the clinical applications of aminolevulinic acid-based photodynamic therapy in female lower genital tract diseases (2022). Photodiagnosis Photodyn Ther. 2022; 39:102993. DOI: 10.1016/j.pdpdt.2022.102993. View

Niu J, Cheng M, Hong Z, Ling J, Di W, Gu L . The effect of 5-Aminolaevulinic Acid Photodynamic Therapy versus CO laser in the Treatment of Cervical Low-grade Squamous Intraepithelial Lesions with High-Risk HPV Infection: A non-randomized, controlled pilot study. Photodiagnosis Photodyn Ther. 2021; 36:102548. DOI: 10.1016/j.pdpdt.2021.102548. View

Brisson M, Drolet M . Global elimination of cervical cancer as a public health problem. Lancet Oncol. 2019; 20(3):319-321. DOI: 10.1016/S1470-2045(19)30072-5. View

Wu A, Niu J, Hong Z, Gu L, Huang Y, Qiu L . The effects of 5-aminolevulinic acid photodynamic therapy on the local immune response of women with cervical intraepithelial neoplasia grade 2. Front Immunol. 2023; 14:1211114. PMC: 10623119. DOI: 10.3389/fimmu.2023.1211114. View

Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P . Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016; 354:i3633. PMC: 4964801. DOI: 10.1136/bmj.i3633. View

Hillemanns P, Garcia F, Petry K, Dvorak V, Sadovsky O, Iversen O . A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2. Am J Obstet Gynecol. 2014; 212(4):465.e1-7. DOI: 10.1016/j.ajog.2014.10.1107. View

Li W, Yang J, Luo L, Jiang M, Qin B, Yin H . Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat Commun. 2019; 10(1):3349. PMC: 6659660. DOI: 10.1038/s41467-019-11269-8. View

10.

Hu Y, Li Y, Xu Y, Teng Y, Chen J, Ma L . Topical 5-aminolevulinic acid photodynamic therapy for cervical high-grade squamous intraepithelial lesions. Photodiagnosis Photodyn Ther. 2022; 39:103037. DOI: 10.1016/j.pdpdt.2022.103037. View

11.

Fu Y, Bao Y, Hui Y, Gao X, Yang M, Chang J . Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection. Photodiagnosis Photodyn Ther. 2015; 13:29-33. DOI: 10.1016/j.pdpdt.2015.12.004. View

12.

Zhang L, Pan K, Huang S, Zhang X, Zhu X, He Y . Graphdiyne Oxide-Mediated Photodynamic Therapy Boosts Enhancive T-Cell Immune Responses by Increasing Cellular Stiffness. Int J Nanomedicine. 2023; 18:797-812. PMC: 9939947. DOI: 10.2147/IJN.S392998. View

13.

Wu A, Li Q, Ling J, Gu L, Hong Z, Di W . Effectiveness of photodynamic therapy in women of reproductive age with cervical high-grade squamous intraepithelial lesions (HSIL/CIN2). Photodiagnosis Photodyn Ther. 2021; 36:102517. DOI: 10.1016/j.pdpdt.2021.102517. View

14.

Nayar R, Wilbur D . The Pap test and Bethesda 2014. Cancer Cytopathol. 2015; 123(5):271-81. DOI: 10.1002/cncy.21521. View

15.

Crane J . Pregnancy outcome after loop electrosurgical excision procedure: a systematic review. Obstet Gynecol. 2003; 102(5 Pt 1):1058-62. DOI: 10.1016/s0029-7844(03)00741-5. View

16.

Gu L, Cheng M, Hong Z, Di W, Qiu L . The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study. Photodiagnosis Photodyn Ther. 2021; 33:102172. DOI: 10.1016/j.pdpdt.2020.102172. View

17.

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View

18.

Kwiatkowski S, Knap B, Przystupski D, Saczko J, Kedzierska E, Knap-Czop K . Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018; 106:1098-1107. DOI: 10.1016/j.biopha.2018.07.049. View

19.

Zhang W, Zhang A, Sun W, Yue Y, Li H . Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia and human papilloma virus infection: A systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore). 2018; 97(21):e10864. PMC: 6392907. DOI: 10.1097/MD.0000000000010864. View

20.

Martin-Hirsch P, Paraskevaidis E, Kitchener H . Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2000; (2):CD001318. DOI: 10.1002/14651858.CD001318. View